2024-06-21 05:11:18 ET
Summary
- ClearPoint Neuro's business continues to perform well despite the stock struggling.
- The drug delivery business is thriving, which should be aided by maturing partner programs and the introduction of new services in coming years.
- The full market release of ClearPoint's operating room and laser solutions should help to revitalize the rest of the business.
- Rapid growth over a multi-year period and a transition to profitability are yet to be priced into the stock.
ClearPoint Neuro's ( CLPT ) business continues to perform well, despite the stock languishing, with ClearPoint's low market capitalization and ongoing losses likely keeping many investors away. This isn't particularly important for the company's long-term prospects though. After raising capital in March, ClearPoint appears to have a clear path to breakeven. The drug discovery business continues to perform well, and the broader release of its operating room and laser solutions should boost the rest of the business....
Read the full article on Seeking Alpha
For further details see:
ClearPoint Neuro: Solid Progress Still Not Reflected In The Share Price